Global Doxorubicin Market Size was $1543.21 Million in 2023

Global Doxorubicin Market Overview

According to Global Market Monitor, the global doxorubicin market size was $1543.21 million in 2023 with a CAGR of 6.23% from 2023 to 2028.Doxorubicin is a kind of antitumor antibiotic that can inhibit the synthesis of RNA and DNA. Doxorubicin is a kind of cycle non-specific drug that affects a wide variety of tumors and kills tumor cells in all sorts of growth cycles. It's given by injection into a vein.

The Increasing Incidence of Cancer has Stimulated the Demand for Doxorubicin.

According to the World Health Organization, cancer is one of the leading causes of death worldwide. Therefore, anticancer drugs will become one of the best-selling products in the international pharmaceutical market. In recent years, Western clinical medical researchers have found that the combination of doxorubicin and cisplatin can effectively control the development of breast cancer. The two old products are very cheap and can be afforded by most patients. The total expenditure of one course is only 1/6 of the cost of using monoclonal antibody anti-breast cancer Hersey J. Therefore, the extremely high-cost performance makes doxorubicin very popular in the international market. The demand for doxorubicin is expected to increase in the coming years.

North America Dominates the Doxorubicin Market.

North America leads the doxorubicin market with a market share of 39.23% in 2023. With the high incidence of breast cancer in North America, the use of doxorubicin will be the biggest driver of its growth. New product launches in the country may also drive the market. For instance, Zydus Cadila received the final approval from the US FDA to market its generic Doxorubicin Hydrochloride Liposome injection, used for treating certain cancers. Thus, due to such factors, the market is expected to grow during the forecast period.

Breast Cancer Occupies the biggest share.

Although doxorubicin is used to treat several types of cancers, breast cancer is the most common one. According to data published by the International Agency for Research on Cancer (IARC), breast cancer represents 1 in 4 cancers diagnosed among women globally. There are 2.3 million women diagnosed with breast cancer and 0.68 million deaths globally. Breast cancer treatments have become the largest consumer of doxorubicin in the past few years, accounting for about 24% of the product's sales share in 2022.

By type	Lyophilized Powder
	Doxorubicin Injection
By application	Ovarian
	Multiple Myeloma
	Kaposi Sarcoma
	Leukemia
	Bone Sarcoma
	Breast
	Gastric
	Liver
	Kidney
	Breast cancer treatments accounted for about 24% in 2022.
By region	North America
	Europe
	Asia-Pacific
	Latin America
	Middle East & Africa
	The North America doxorubicin market is expected to grow during the forecast period.

For more industry information, please refer to our latest released "China Doxorubicin Industry Market Research Report 2023-2029".